This bill creates a five-year pilot program to provide grants to states and local governments for expanding Forensic Assertive Community Treatment teams. These specialized teams offer intensive, round-the-clock support including mental health care, addiction treatment, and housing assistance to individuals with serious mental illness who are involved with the criminal justice system. The program requires teams to include a mix of psychiatrists, employment specialists, criminal justice partners, and peer specialists with lived experience. Additionally, the legislation authorizes funding for a study by the National Academies to evaluate the program's effectiveness and develop guidelines for scaling it up.
The Expedited Access to Biosimilars Act modifies federal regulations to streamline the approval process for biosimilar drugs, which are lower-cost versions of existing biologic medicines. The bill requires manufacturers to conduct specific studies on how the drug behaves in the body and how the immune system reacts to it, while limiting the need for additional large-scale clinical trials unless the FDA explicitly determines they are necessary. To ensure transparency, the law mandates that the FDA must provide written notice to drug sponsors within 60 days regarding whether extra studies are required. These changes aim to reduce the time and cost involved in bringing biosimilars to market, potentially increasing patient access to affordable treatment options.
This bill establishes a new coordinator within the President's Domestic Policy Council to lead federal efforts in using artificial intelligence to improve the diagnosis, treatment, and prevention of pediatric cancer. The coordinator will specifically work with the Childhood Cancer Data Initiative to enhance clinical trials, consolidate medical data for better analysis, and develop new tools that predict how patients respond to treatments. Additionally, the legislation directs the Health and Human Services Secretary to create interoperability standards that allow patient data to be safely shared for AI research while ensuring individuals maintain control over their health information. The bill authorizes funding for these initiatives through fiscal years 2027 to 2031 and requires a report to Congress on implementation within 180 days of enactment.
The Protecting Americans' Health Care Act of 2026 reverses specific Medicaid changes made in the 119th Congress. It directly affects state and federal health programs by restoring the original rules that were previously altered. The bill achieves this by repealing the relevant sections of the reconciliation law and reinstating the prior legislation as if the changes had never occurred. This action effectively undoes the policy shifts related to Medicaid funding and eligibility that were implemented in the earlier session.
This resolution expresses the House of Representatives' support for maintaining equity, diversity, and inclusion in federally funded health research to improve scientific quality and patient outcomes. It opposes proposed administrative rules that would allow political appointees to override peer reviews, restrict international collaborations, and ban funding for studies on diversity and health disparities. The text highlights historical data showing that excluding women and people of color from research has led to medical gaps, such as inaccurate diagnostic tools for Black patients and delayed diagnoses for women with heart disease. Ultimately, the bill urges the administration to preserve the current science-based peer review system and remove barriers that prevent underserved communities from benefiting from medical advancements.
The Cure Hepatitis C Act of 2026 establishes a federal program to eliminate hepatitis C by creating a subscription model that allows the government to purchase antiviral drugs directly from manufacturers and distribute them at no cost to specific patient groups. These groups include individuals in Medicaid or CHIP programs, those without health insurance, patients in correctional facilities, and those receiving care through the Indian Health Service. The bill also expands Medicare coverage by removing deductibles and copayments for hepatitis C treatments between 2028 and 2032. To support these efforts, the legislation authorizes funding for state grants to improve screening and treatment access, mandates the creation of a national strategy and performance dashboard, and requires coordination with various federal agencies and stakeholders.
The Examining Opioid Treatment Infrastructure Act of 2026 directs the Comptroller General of the United States to conduct a study on the nation's capacity for treating opioid-use disorders. This evaluation will assess the availability of inpatient and outpatient programs, including detoxification, stabilization, and rehabilitation services, with specific attention to geographic gaps and needs for specific demographics like pregnant women and American Indians. The report will also examine the use of evidence-based treatments and identify barriers to reporting real-time overdose data. Ultimately, the bill aims to provide Congress with a comprehensive overview of current treatment resources and challenges within the healthcare system.
This bill authorizes the Department of Veterans Affairs to build or renovate a community-based outpatient clinic in Saipan, Northern Mariana Islands, using up to $3.696 million in fiscal year 2027. The legislation allows the VA to use flexible building standards suited to the island's unique geographic and logistical challenges, such as the need for ocean transport of materials and limited local contractors. It specifically aims to address the current lack of a permanent VA clinical presence in the region and reduce the burden on veterans who must travel long distances for care. Ultimately, the act provides funding and regulatory flexibility to establish a local medical facility for veterans living in the Commonwealth of the Northern Mariana Islands.
The Essential Caregivers Act of 2026 requires nursing homes, long-term care hospitals, rehabilitation facilities, and intermediate care facilities to allow two chosen family members or friends to visit residents during times when regular visitation is suspended. These essential caregivers must agree to follow the facility's existing safety and infection control rules, which are no more restrictive than those applied to staff. While facilities can limit access for the first seven days of a suspension or deny entry if a caregiver shows symptoms of a serious infectious disease, they cannot block visits for end-of-life care. Additionally, the bill mandates that complaints about denied access to essential caregivers be investigated and resolved within three days.
The REDACT Act amends the Epstein Files Transparency Act to allow private individuals to sue the federal government if their personal or medical information is improperly disclosed in released documents. Under this new provision, victims can file a civil lawsuit against the United States if an official fails to redact data that would constitute an unwarranted invasion of privacy. If a person wins the case, they could receive up to $50,000 for each violation, plus compensation for emotional distress and legal fees. The law applies to violations occurring on or after November 19, 2025, and gives plaintiffs five years from the date they learn of the breach to file a claim.
